Warning letter
DuPont Nutrition USA Inc.: warning letter of Dec 2, 2022
FDA warning letter 627211 · Division of Pharmaceutical Quality Operations I
Key facts
| Reference number | 627211 |
|---|---|
| Company | DuPont Nutrition USA Inc. |
| Subject | CGMP/Drug Products/Adulterated |
| Issue date | Dec 2, 2022 |
| Posted date | Dec 20, 2022 |
| Issuing office | Division of Pharmaceutical Quality Operations I |
| Product type | Drugs |
| Inspection city | Newark |
| Inspection ZIP | 19711 |
| Inspection start date | Nov 17, 2021 |
| Letter on fda.gov | fda.gov |
At a glance
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: